A look at Acadia Pharmaceuticals Inc’s (ACAD) recent performance gives investors their first glimpse of hope.

On Friday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was unchanged from the session before settling in for the closing price of $17.26. A 52-week range for ACAD has been $14.15 – $32.59.

Healthcare Sector giant saw their annual sales surged by 27.73% over the last five years. When this article was written, the company’s average yearly earnings per share was at 296.71%. With a float of $164.30 million, this company’s outstanding shares have now reached $166.35 million.

The firm has a total of 598 workers. Let’s measure their productivity. In terms of profitability, gross margin is 91.61%, operating margin of 12.08%, and the pretax margin is 14.71%.

Acadia Pharmaceuticals Inc (ACAD) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Acadia Pharmaceuticals Inc stocks. The insider ownership of Acadia Pharmaceuticals Inc is 1.26%, while institutional ownership is 93.77%. The most recent insider transaction that took place on Nov 19 ’24, was worth 173,630. In this transaction EVP, COO, HEAD OF COMMERCIAL of this company sold 10,329 shares at a rate of $16.81, taking the stock ownership to the 62,105 shares. Before that another transaction happened on Nov 19 ’24, when Company’s PRINCIPAL ACCOUNTING OFFICER sold 4,073 for $16.81, making the entire transaction worth $68,467. This insider now owns 19,863 shares in total.

Acadia Pharmaceuticals Inc (ACAD) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 296.71% per share during the next fiscal year.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators

You can see what Acadia Pharmaceuticals Inc (ACAD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.09. Likewise, its price to free cash flow for the trailing twelve months is 14.17.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.23 in the next quarter and is forecasted to reach 0.76 in one year’s time.

Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)

Analysing the last 5-days average volume posted by the [Acadia Pharmaceuticals Inc, ACAD], we can find that recorded value of 2.18 million was better than the volume posted last year of 1.67 million. As of the previous 9 days, the stock’s Stochastic %D was 48.51%. Additionally, its Average True Range was 0.73.

During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 58.79%, which indicates a significant increase from 40.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.10% in the past 14 days, which was higher than the 51.17% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $15.98, while its 200-day Moving Average is $16.68. Now, the first resistance to watch is $17.54. This is followed by the second major resistance level at $17.82. The third major resistance level sits at $18.20. If the price goes on to break the first support level at $16.88, it is likely to go to the next support level at $16.50. Should the price break the second support level, the third support level stands at $16.22.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats

There are 166,392K outstanding shares of the company, which has a market capitalization of 2.87 billion. As of now, sales total 726,440 K while income totals -61,290 K. Its latest quarter income was 250,400 K while its last quarter net income were 32,770 K.